thymosin beta-4 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming is inconsistent across suppliers and publications |
| Reported sequence | Ac-LKKTETQ | Corresponds to residues 17-23 of the parent protein |
| Frequently cited registry number | 77591-33-4 | Associated with full-length thymosin beta-4 rather than the fragment |
| Common supplied form | Freeze-dried solid | Often presented as an acetate or trifluoroacetate salt |
| Regulatory treatment | Varies by country | Frequently handled as a research chemical; not broadly approved as a therapeutic |
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Die toxische Wirkung von P. parvum u. a für Fische wird auf eine Gruppe organo-chemischer Verbindungen zurückgeführt, die Prymnesine genannt werden und chemisch Polyether mit einer großen Leiterrahmenstruktur (englisch supersized ladder-frame polyether compounds) sind. Es sind biochemisch komplexe und hochmolekulare Verbindungen. Diese Prymnesine werden derzeit (Stand 2024) in drei Typen A, B und C unterteilt (9 vom A-Typ, 12 vom B-Typ und 30 vom C-Typ). Es ist gut möglich, dass bisher noch nicht alle von dieser Alge abgesonderten Toxine identifiziert wurden. Sie zeigen starke zytotoxische, hämolytische, neurotoxische und ichthyotoxische Wirkungen. Bei Stress sondert die P. parvum diese chemischen Verbindungen in das Wasser ab. In Verbindung mit im Wasser befindlichen Kationen (z. B. Magnesium-Ionen Mg++ oder Calcium-Ionen Ca++) bilden sich dann die effektiven Toxine. Diese sind also abhängig von der Chemie des Wassers, wobei meist eine Kombination verschiedener Toxine vorhanden ist. Die genaue Zusammensetzung, d. h. der Anteil eines jeden der verschiedenen Prymnesine hängt vom jeweiligen Stamm von P. parvum ab. Der Stamm K-0081 enthielt ca. 5-mal mehr Toxin als der Stamm K-0374. Im August 2024 identifizierten Timothy R. Fallon et al. die Prymnesin-produzierenden Proteine von P. parvum, große Polyketid-Synthasen (PKS), genannt PKZILLAs. PKZILLA-1 besteht aus 45.212 Aminosäure-Bausteinen (entsprechend 4,7 Megadalton) und ist damit nachweislich das größte von einem Organismus produzierte Protein, insbesondere größer als das menschliche Titin; PKZILLA-1 hat 140 Enzym-Domänen.
PKZILLA-2 hat noch 3,2 Megadalton und 99 Enzym-Domänen. Diese beiden PKZILLAs sind beteiligt an der Synthese von Prymnesinen des Typs A; das in P. parvum RCC3426 gefundene PKZILLA-B1 ist dagegen verantwortlich für die Synthese von Prymnesin-B1.
=== Nutzen der Toxine für die Alge und Schaden für andere === Diese Toxine könnten als Gifte wirken, die es diesen Algen ermöglichen, andere einzellige Organismen zu fangen, um sie zu fressen (phagocytieren). Man vermutet, dass es ihre Funktion ist, Beutetiere zu verlangsamen oder unbeweglich zu machen, damit die Algen sie dann erbeuten können. Werden die Toxine aber von einer großen Menge Algen massiv ins Wasser abgegeben, dann wirken sie auch auf höhere tierische Organismen wie Fische. Angegriffen werden zuerst schlecht geschützte und exponierte Zellen, z. B. auf der Oberfläche der Kiemen von wirbellosen Wassertieren und von Fischen sowie auf deren Flossen. Sie verhindern die ordnungsgemäße Funktion der Wasserregulierung in der Zelle (Osmoregulation), die durch Vergiftung und/oder Wasserüberschuss abstirbt. Nachdem die erste Zellschicht zerstört ist, werden die nächsten Schichten angegriffen. Wenn ein Blutgefäß betroffen ist, kommt es zur Blutung. Durch die erodierten Kiemen gelangen die Toxine in das Blut- und Kreislaufsystem des Fisches. In der Folge werden auch die inneren Organe geschädigt. Die ersten sichtbaren Symptome sind, dass der Fisch sich wie bei Sauerstoffmangel im Wasser verhält; er pendelt zwischen der Oberfläche, wo er nach Luft zu schnappen versucht, und dem Grund, wo er ruht und stirbt. Neuere Erkenntnisse zeigen, dass diese Art nur unter Umweltstress Toxine produziert, z. B. bei einem Überangebot an planktischen Räubern (Zooplankton) oder Dinoflagellaten der Spezies Oxyrrhis marina (Oxyrrhinales). Offenbar benutzt P.
parvum die Toxine in diesem Fall zur Abwehr der eigenen Fressfeinde. Jedenfalls nahmen die Dinoflagellaten weniger P. parvum als Nahrung auf als andere marine Algen, etwa Cryptophyceen der Gattung Rhodomonas. Die Toxine bewirken offenbar eine Verlangsamung der Aufnahme- und Verdauungskapazität von Dinoflagellaten. In ähnlicher Weise kann Stress durch einen Mangel an Stickstoff oder Phosphor die Produktion von Toxinen auslösen. Vermutlich profitiert P. parvum dann nicht nur durch leichteres Beutemachen, sondern auch von den Spurenelementen, die von abgestorbenen Individuen der anderer Arten freigesetzt werden – dies könnte ein Weg sein, um in einer Umgebung konkurrenzfähiger zu sein.
Sources: de.wikipedia.org
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.
Very few controlled human studies focus on the seven-residue sequence itself. Most clinical data concern the full-length protein in cardiac or ophthalmic settings. Conclusions drawn for one form should not be assumed to transfer to the other.
Detection normally relies on reversed-phase liquid chromatography paired with mass spectrometry. Chromatographic retention time establishes the expected elution window, and the mass spectrum confirms the molecular ion. Immunoassays exist but can cross-react with related peptides.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.